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Extracellular vesicles (EVs) are nano-sized, lipid bilayer-enclosed particles involved in intercellular communication. EVs are increasingly
being considered as drug delivery vehicles or as cell-free approach to regenerative medicine. However, one of the major challenges for their
clinical application is finding a scalable EV isolation method that yields functional EVs. Although the golden standard for EV isolation is
ultracentrifugation (UC), a recent study suggested that isolation using size-exclusion chromatography (SEC) yielded EVs with more intact
biophysical properties. Whether this also leads to differences in functionality remained to be investigated. Therefore, we investigated possible
differences in functionality of cardiomyocyte progenitor cell-derived EVs isolated using UC and SEC. Western blot analysis showed higher
pERK/ERK ratios in endothelial cells after stimulation with SEC-EVs compared to UC-EVs, indicating that SEC-EVs bear higher
functionality. Therefore, we propose to use SEC-EVs for further investigation of EVs' therapeutic potential. Further optimization of isolation
protocols may accelerate clinical adoption of therapeutic EVs.
© 2017 Elsevier Inc. All rights reserved.
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1549-9634/© 2017 Elsevier Inc. All rights reserved.recipient cell behavior, and affect physiological and pathological
processes.1-3 For this reason, EVs are increasingly being
considered for therapeutic purposes, including cell-free ap-
proaches for regenerative medicine and drug delivery.4-6 The
interest in using EVs for cardiac therapy increased after it
became clear that the beneficial effects of stem cell therapy after
a myocardial infarction (MI) were mainly due to paracrine
actions.7 EVs were identified to be the major component of the
stem cell secretome responsible for the observed increase in
cardiac function.8 Therefore, using EVs as an off-the-shelf
therapeutic may circumvent some of the drawbacks of cell based
therapy, such as cell survival, retention, rejection, and the use of
replicating cells.
One of the major challenges for implementation of EVs as
therapeutics is the development of a scalable, reproducible, and
standardizable isolation method that results in an acceptable yield
of EVs. To date, the most common EV isolation method is
differential ultracentrifugation (UC). This method relies onlar vesicles isolated using size-exclusion chromatography compared to
/10.1016/j.nano.2017.03.011
Figure 1. Schematic overview of EV isolation protocols used in this study. Abbreviations: CM = conditioned medium, SEC = size-exclusion chromatography,
UC = ultracentrifugation.
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(extra)cellular components. Although the UC protocol is relatively
straightforward, it is also time consuming, andmay yield aggregated
EVs after pelleting.9,10 Furthermore, UC isolation results in low and
operator-dependent yields and EVs can be damaged due to shearing
forces, as a result of centrifugation at high speeds.11,12 An additional
method for EV isolation, based on ultrafiltration and size-exclusion
chromatography (SEC) to separate EVs from other media
components, was recently suggested by Nordin et al.13 EVs isolated
using chromatography (SEC-EVs) are more intact than EVs isolated
using UC (UC-EVs), likely due to the absence of centrifugation at
high speeds.Whether this also leads to differences in functionality of
SEC- and UC-EVs remained to be investigated.
Methods
A detailed version of the Methods is available online under
Supplementary Material.
Results
In order to investigate whether the isolation protocol affects EV
functionality, EVs derived from cardiomyocyte progenitor cells
(CPCs)were isolated usingUCandSEC.CPCs are being intensively
investigated for cardiac-related therapies, and CPC-derived EVs
have previously been shown to bear pro-angiogenic properties.14-16
A schematic representation of the UC and SEC isolation protocols
used in this study is shown in Figure 1.
First, EV yield was compared by quantification of EV protein
content and number of particles, as shown in Figure 2, A. No
significant differences in total EV protein or particle yield between
UC and SEC were found. This is in contrast with previous
observations showing that SEC isolation results in a higher EV
yield compared to UC isolation.13 This may be explained by
variation between cell types or due to slight differences in UC or
SEC isolation procedure (e.g., rotor/filter type or pore size). Next,
UC-EVs and SEC-EVs were characterized based on size
distribution, morphology, and the presence or absence of proteinmarkers. Figure 2, B shows a representative size distribution
profile of UC-EVs and SEC-EVs based on Nanoparticle Tracking
Analysis. SEC-EVs had a smaller size distribution with the highest
peak at approximately 90 nm, compared to a broader size range for
UC-EVs, peaking at approximately 100 nm. Transmission
electron microscopy analysis showed no major morphological
differences between UC-EVs and SEC-EVs, as both preparations
contained both smaller and larger vesicles (Figure 2, C). Western
blot analysis revealed that both UC-EVs and SEC-EVs were
enriched for EV marker proteins Alix and CD63, but not TSG101
(Figure 2, C). Although the expected band for Alix (96 kDa) was
present for both UC-EVs and SEC-EVs, an extra band at 90 kDa
was observed in the UC-EV preparation. The presence of double
bands for Alix may be explained by differential phosphorylation
status, as Alix is known to have multiple phosphorylation sites.17
Why this second band was exclusively found in UC-EVs remains
unclear, but might suggest a different vesicle sub-class or
activation status. The endoplasmatic reticulum protein calnexin
was only detected in the cell lysate, confirming the absence of
contamination with other membrane compartments in EVs.
β-Actin was found in similar levels in EVs and cell lysate.
CPC-derived EVs have previously been shown to stimulate
migration of human microvascular endothelial cells (HMECs) in a
scratch wound assay.14 As the mitogen-activated protein kinase1/2
(MAPK1/2)–extracellular signal-regulated kinase1/2 (ERK1/2)
pathway is known to play an important role in cell survival,
migration and angiogenesis during wound healing,18-20
EV-induced ERK1/2 phosphorylation was used as a read-out to
evaluate the possible differences in functionality of UC-EVs and
SEC-EVs. To investigate the functionality of EV preparations,
HMECswere stimulated with UC-EVs and SEC-EVs (Figure 3,A).
Due to a lack of consensus in the EV-field on the most accurate
method for EV quantification, HMECs were stimulated with both
equal amounts of UC-EV and SEC-EV protein (Figure 3, B), and
equal numbers of EV particles (Figure 3, C). Levels of
phosphorylated ERK1/2 and total ERK1/2 were determined using
Western blotting, after which pERK/ERK ratios were calculated. A
dose-dependent increase in ERK phosphorylation was observed for
Figure 2. Characterization of UC-EVs and SEC-EVs. (A) EV yield as determined by microBCA analysis (EV protein, upper panel) and Nanoparticle Tracking
Analysis (NTA) (EV particle number, lower panel). Statistical analysis was performed using an unpaired Student's t test. (B) Size distribution profile of UC-EVs and
SEC-EVs as determined by NTA. (C) Transmission electron microscopy pictures of UC-EVs and SEC-EVs. Scale bar = 100 nm. (D) Western blot of UC-EVs,
SEC-EVs and cell lysate (CL). Abbreviations: CL = cell lysate, MW = molecular weight, SEC = size-exclusion chromatography, UC = ultracentrifugation.
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ERK ratio compared to 1 μg SEC-EVs (2.1 ± 0.3 for 3 μg
SEC-EVs vs 1.2 ± 0.2 for 1 μg SEC-EVs). Moreover, stimulation
with 3 μgSEC-EVs resulted in a higher pERK/ERK ratio compared
to stimulation with 3 μg of UC-EVs (2.1 ± 0.3 for SEC-EVs vs
1.0 ± 0.2 for UC-EVs). The same trend was observed after adding
equal numbers of EV particles to HMECs (Figure 3,C). Stimulation
of HMECs with 6.1010 SEC-EVs resulted in higher pERK/ERK
ratio compared to 6.1010 UC-EVs (3.56 ± 1.29 for SEC particles vs
1.42 ± 0.24 for UC particles). These results show that CPC-derived
SEC-EVs have higher functionality compared to UC-EVs.Discussion
The striking difference in functionality between UC-EVs and
SEC-EVs may result from the high shear forces that are applied
during high speed centrifugation during UC isolation. These maydetrimentally affect signalingmolecules on theEV surface, thereby
preventing UC-EVs to activate, bind to or be taken up by recipient
cells. Indeed, UC-EVs have previously been described to appear
ruptured when studied using transmission electronmicroscopy and
fluorescence correlation spectroscopy.13 Furthermore, the size
distribution profile of SEC-EVs also differed from UC-EVs, as
SEC-EVs were found to be smaller in size compared to UC-EVs.
The apparent larger size may be the result of aggregation or fusion
of EVs during UC, as also suggested by others.9,11-13 Alternative-
ly, UC isolation may enrich for larger EVs that sediment more
efficiently. Whether and how this contributes to EV functionality
remains to be investigated. Furthermore, as characteristics of
isolated EVs vary between cell types, differences in functionality
between SEC-EVs and UC-EVs may be cell type-dependent. This
needs to be addressed in future studies.
In this study, we used induction of ERK phosphorylation as
an outcome parameter to assess EV functionality, as activation of
HMECs via pERK has been shown to be indicative for the
Figure 3. Assessment of UC-EV and SEC-EV functionality. (A) HMECs were stimulated with EVs for 30 min, after which phosphorylated ERK1/2 and total
ERK1/2 protein levels were determined usingWestern blotting. (B) Stimulation of HMECs with equal amounts of UC-EV and SEC-EV protein. (C) Stimulation
with equal numbers of UC-EV and SEC-EV particles. Abbreviations: ERK = extracellular signal-regulated kinase, SEC = size-exclusion chromatography,
UC = ultracentrifugation.
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may be contaminated with other soluble materials that affect
ERK phosphorylation. Although we cannot exclude this
completely, Western blot analyses as well as protein and particle
number measurements indicate that SEC isolation allows for EV
preparations with similar purity as UC (Figure 1, A, D).
Additionally, CPC-EVs may affect other processes involved in
cardiac disease, as treatment with CPC-EVs has been shown to
result in increased cardiac function after MI in mice by
enhancing angiogenesis, as well as reducing cardiomyocyte
apoptosis.16 Whether SEC-EVs display increased functionality
for cardiac repair in vivo, as well as for other therapeutic
strategies, therefore remains to be investigated.
In conclusion, one of the major challenges for developing EV
therapeutics is finding a scalable isolation method that yields
EVs with high functionality. Although previous reports already
suggested that EV function might be affected by the isolation
procedure, to our knowledge, we are the first to show that EV
isolation technique can actually affect their functionality. SEC
isolation results in more functional EVs compared to UC
isolation, which is especially important when developing EVs as
therapeutics.Acknowledgments
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